The lawsuit centers on a two-day erosion of equity value that saw Erasca shares tumble from $21.49 on April 24, 2026, to $9.90 by the close of April 28. Investors allege the company artificially inflated prices during a $258.8 million common stock offering in January 2026 by concealing material risks related to its ERAS-0015 drug candidate. Central to the complaint are allegations that Erasca misrepresented the drug's superiority over Revolution Medicines' competing product and failed to disclose a fatal adverse event in a Phase 1 trial.

For pension funds and asset managers, the decline raises significant questions regarding fiduciary obligations to recover portfolio losses. The pending action, filed in the U.S. District Court for the Southern District of California, asserts violations of the Securities Exchange Act. Institutional holders have until August 10, 2026, to apply for lead plaintiff status, a position that grants oversight of litigation strategy and settlement negotiations without requiring out-of-pocket costs.